Zogenix to Release Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 5
Zogenix, a global pharmaceutical company, will announce its financial results for Q2 2020 on August 5, 2020, at 4:30 PM ET. The company is focused on developing therapies for rare diseases, with its approved product FINTEPLA for treating Dravet syndrome and ongoing late-stage programs for Lennox-Gastaut syndrome and TK2 deficiency. The conference call will be accessible through toll-free and international numbers, alongside a webcast link.
- FINTEPLA approved by the U.S. FDA for Dravet syndrome, expanding product portfolio.
- Late-stage development programs for additional rare disease therapies.
- None.
EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will host a corporate update conference call and webcast on Wednesday, August 5, 2020, at 4:30 PM Eastern Time.
| Conference Call Details | |
| Wednesday, August 5, at 4:30 PM Eastern Time / 1:30 PM Pacific Time | |
| Toll Free: | 866-269-4260 |
| International: | 323-347-3612 |
| Conference ID: | 8881331 |
| Webcast: | http://public.viavid.com/index.php?id=141049 |
About Zogenix
Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, C-IV has been approved by the U.S. FDA and is under review in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. In addition, the company has two late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a rare childhood-onset epilepsy and one for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.
CONTACTS:
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
FAQ
When will Zogenix report its Q2 2020 financial results?
What is Zogenix's stock symbol?
What therapies is Zogenix developing?
How can I access Zogenix's financial results conference call?
